Samsung Bioepis Said to Acquire U.S. Biogen’s Biosimilar Unit
SEOUL, Aug. 2 (Korea Bizwire) — Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has been in talks with Biogen Inc. to buy the U.S. biotech firm’s biosimilar business unit, industry sources said Wednesday. Through the deal with the Nasdaq-listed firm, Samsung Bioepis seeks to secure a direct sales network in the United [...]